Eli Lilly stock
LLYNYSEEli Lilly and Company, HealthcareISIN US5324571083
85Score 85 out of 100, Strong
Price and trend
83 / 100
Price history
+40% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is at its 52-week high. Largest decline in 20 years: 55% (April 2007 to March 2009).
Chart figures for advanced users
- SMA 50$1,235.40
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1,107.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$851.21
- The lowest closing price of the last twelve months.
- Resistance$1,437.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Eli Lilly and Company belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $1.34T, is the largest of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $65.18B (up 44.7% year on year) and earnings of $20.64B (up 94.9%).
- For fiscal 2026, analysts expect on average revenue of $91.1B (up 39.8%) and adjusted earnings per share of $35.33 (up 45.9%).
Show more
- MEQIRI Score 85 out of 100 (Strong): rank 5 of 702 in Healthcare, median 53.
- The P/E is 46.2 (Drug Manufacturers (General) median 25.7, own median of recent years 46.6).
- Our model puts fair value at $1,094.65, with the price 30% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 54 years.Capital allocation 96
- High return on capitalReturn on invested capital 44.8% in fiscal 2025, Drug Manufacturers (General) median 13.4%.Profitability 99
- Earnings per share growingUp 29% a year since 2020.Growth 100
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are growth and profitability, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among the 100 largest stocks.
From 2016 to 2025, 7 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- very large company
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $842.04 and expensive above $1,563.79 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $1,395.32 (cash-flow model) and $793.99 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $963.64, at 7.8% it would be $1,292.52.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 45.5% on the twelve months before. Revenue has grown solidly since 2006, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 83%, operating 46%, net 32%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 29 Oct 2026EPS reported $7.48 (expected $5.71)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.6% since 15 Oct 2026.
- Earnings per share
- $35.33+1.0%
- Revenue
- $91.1B+2.7%
- Earnings per share
- $50.00+5.6%
- Revenue
- $106.45B+3.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +10.0%Eli Lilly raised its 2026 guidance: revenue now expected at 91 to 92 billion dollars and earnings per share at 35 to 36 dollars, both higher than previously expected.
“Based on a strong underlying performance across our portfolio, we now expect full year revenue to be between $91 and $92 billion We saw strength in The U.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $25.85M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Eli Lilly
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 85
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next smaller companies by market value
- Johnson & JohnsonJNJ $682.52B75
- AbbVieABBV $520.47B74
- Roche HoldingROP.SW $394.85B77
- MerckMRK $362.27B68
- NovartisNOVN.SW $304.26B75
- AstraZenecaAZN $285.95B73
- AmgenAMGN $252.64B76
- Gilead SciencesGILD $208.31B57
ETFs that hold Eli Lilly
Held by 131 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 16.78% | 0.15% | €3.29B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 16.77% | 0.12% | €1.39B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 16.30% | 0.15% | €599.59M |
Show 5 more
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 11.86% | 0.25% | €4.12B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 11.78% | 0.18% | €839.61M |
| Harbor Health Care UCITS ETF AccW311 | 8.68% | 0.89% | €11.72M |
| iShares Edge MSCI USA Quality Factor UCITS ETFQDVB | 4.38% | 0.20% | €1.91B |
| UBS Factor MSCI USA Quality Screened UCITS ETF USD disUBUT | 4.18% | 0.25% | €1.16B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.